TY - JOUR
AU - RECOVERY Collaborative Group
PY - 2023
DA - October
TI - Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
JO - The Lancet Diabetes & Endocrinology
EP - 914
VL - 11
IS - 12
DO - https://doi.org/10.1016/S2213-8587(23)00253-X
AB - BackgroundEmpagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
PB - Elsevier
UR - https://hdl.handle.net/10023/31963
KW - Coronavirus (COVID-19)
KW - Hospital care
ER